Flamel Ireland Limited
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 26, 2027The maintenance fee for Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics (US 11,766,418) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due Apr 10, 2027The maintenance fee for Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics (US 11,779,557) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics (US 11,826,335) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Modified Release Gamma- Hydroxybutyrate Formulations Having Improved Pharmacokinetics (US 11,839,597) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for N-Phosphonomethylglycine Guanidine Derivative Salts (US 9,233,993) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics (US 11,896,572) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Compound embodiments for hydrogen sulfide production and methods of making and using the same (US 11,981,626) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 23, 2026
- Nov 17 US 12,797,353 Modified Release Gamma- Hydroxybutyrate Formulations Having Improved Pharmacokinetics
- Oct 20 US 12,766,122 Modified Release Gamma- Hydroxybutyrate Formulations Having Improved Pharmacokinetics
- Sep 8 US 12,728,110 Modified Release Gamma- Hydroxybutyrate Formulations Having Improved Pharmacokinetics
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE47,084 | Oral Medicinal Product with Modified Release of at Least One Active Principle in Multimicrocapsular Form In force · Low confidence | In force | Low confidence | |
| US 8,507,003 | Compressed tablets comprising microcapsules with modified release In force · High confidence | In force | High confidence | |
| US 10,092,511 | Controlled-Release Floating Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 9,775,355 | Guanidine Derivative Compounds In force · High confidence | In force | High confidence | |
| US 9,561,179 | Controlled-Release Floating Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 11,602,512 | Modified Release Gamma- Hydroxybutyrate Formulations Having Improved Pharmacokinetics In force · Low confidence | In force | Low confidence | |
| US 11,826,335 | Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics In force · High confidence | In force | High confidence | |
| US 11,839,597 | Modified Release Gamma- Hydroxybutyrate Formulations Having Improved Pharmacokinetics In force · High confidence | In force | High confidence | |
| US 12,115,145 | Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics In force · Medium confidence | In force | Medium confidence | |
| US 12,144,793 | Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 59: 8 patents in force now held by others · 9 lapsed for an unpaid fee · 8 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 16 abandoned · 2 no status recorded